Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Krka Spells Out Chinese Potential With Plans To Double Portfolio In 2022

Slovenian Firm Also Plans To Regroup In West Europe After 11% Sales Tumble

Executive Summary

Alongside discussing the firm’s preliminary financial results for 2021, Krka management explained how the company planned to make further inroads in China in 2022 and return to its 2020 revenue baseline in West Europe, following a dip last year.

You may also be interested in...



Krka Delivers On Pledge To Publish Five-Year Business Plan

Slovenian firm Krka wishes to strengthen and optimize its vertically integrated business model over the next five years, just one of many goals just published by the company under a new business plan to 2026.

Krka Welcomes ‘Highest Ever Net Profit’ As EBITDA Jumps By 30%

Slovenia’s Krka saw business boom as it rushed to supply the demand created by the coronavirus pandemic, while reaping the benefits from its vertically integrated business model. CEO and president of the management board Jože Colarič has just been appointed for another six-year term.

Krka offers an update on its Chinese venture

Krka says it is making progress with its operations in China, after the Slovenian firm revealed initial short-term goals for its local business. The company established its Ningbo Krka Menovo joint venture with Chinese player Ningbo Menovo late last year (Generics bulletin, 24 November 2017, page 3).

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel